Welcome to the e-CCO Library!

P366: Escherichia coli Nissle 1917 in ulcerative colitis treatment: systematic review and meta-analysis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Losurdo*, A. Iannone, A. Contaldo, E. Ierardi, A. Di Leo, M. Principi

Created: Friday, 22 February 2019, 9:49 AM
P366: Exclusive enteral nutrition drives protective microbiome modulation in paediatric Crohn's Disease
Year: 2022
Source: ECCO'22
Authors: Häcker, D.(1);Siebert, K.(2);Metwaly, A.(1);Hölz, H.(2);De Zen, F.(2);Köhler, N.(3);Pauling, J.K.(3);Matchado, M.(4);List, M.(4);Schwerd, T.(2);Haller, D.(1,5);
Created: Friday, 11 February 2022, 3:52 PM
P366: genomics analysis and differentiation of Crohn's Disease, Intestinal Tuberculosis and Primary Intestinal Iymphoma
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lin, L.(1)*;Qu, Y.(2);Zhao, X.(1);
Created: Friday, 14 July 2023, 11:05 AM
P366: Long-term evolution of gastrointestinal immune-related adverse events (GI-IrAE) induced by immune checkpoint inhibitors (ICI)
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. de Malet1*, G. Antoni2, E. Soularue1, M. Collins1, L. Marthey1, T. Vaysse1, C. Mateus3, C. Robert3, F. Carbonnel1

Created: Thursday, 21 February 2019, 9:14 AM
P366: The efficacy of vedolizumab for induction of clinical response and remission in anti-TNF naïve patients with inflammatory bowel disease – a multicenter European real world experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kopylov U.*1, Sebastian S.2, Ron Y.3, Steinhagen P.R.4, Roblin X.5, Pugliese D.6, Bar-Gil Shitrit A.7, Katsanos K.8, Fiorino G.9, Allocca M.10, Sipponen T.11, Ungar B.12, Armuzzi A.6, Eliakim R.12, Christodoulou D.8, Baumgart D.C.4, Ben-Horin S.12, Dotan I.3

Created: Wednesday, 20 February 2019, 10:36 AM
P366: Vedolizumab maintenance therapy reduced use of corticosteroids in patients with Crohn’s disease in the GEMINI 2 trial
Year: 2021
Source: ECCO'21 Virtual
Authors: D'Haens, G.(1);Candela, N.(2);Uddin, S.(3);Peterson, T.(2);Dubinsky, M.(4);Colombel, J.F.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P367 Real-life long-term effectiveness and treatment persistence of vedolizumab in a single tertiary care cohort of Crohn’s disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Calandrini, M. Salice, H. Privitera Hrustemovic, G. Peruzzi, F. Rizzello, C. Calabrese, E. Scaioli, A. Belluzzi, P. Gionchetti

Created: Thursday, 30 January 2020, 10:12 AM
P367: Lower quality of life, more active disease and increased healthcare costs due to non-adherence in inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Severs*1, M.-J. Mangen2, H. H. Fidder1, M. E. van der Valk1, M. van der Have1, A. A. van Bodegraven3, 4, C. H. M. Clemens5, G. Dijkstra6, J. M. Jansen7, D. J. de Jong8, N. Mahmmod9, P. C. van de Meeberg10, A. E. van der Meulen- de Jong11, M. Pierik12, C. Y. Ponsioen13, M. J. L. Romberg- Camps3, P. D. Siersema1, J. R. Vermeijden14, J. van der Woude15, P. N. Zuithoff16, B. Oldenburg1

Created: Friday, 22 February 2019, 9:49 AM
P367: Nutrition advice for IBD patients as a useful complementary strategy: a single-centre cohort intervention
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Fortuna1, M. Di Ruscio*1, A. Variola1, A. Massella1, A. Geccherle1

Created: Friday, 22 February 2019, 9:41 AM
P367: quality of life in patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Salem, J.(1);Ghandour, F.(2);Halabi, M.T.(3);Douaihy, T.(1);Matta, J.(4);Bedran, K.(5);Farhat, S.(5);
Created: Friday, 11 February 2022, 3:52 PM
P367: Significant impact on health care utilization upon implementation of an electronic IBD care management program.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Koppelman, L.(1)*;Roozemoind, S.(1);Cornelissen, L.(2);Hommes, D.(2);Voorneveld, P.(1);Maljaars, J.(1);Kubben, F.(3);Verweij, E.(3);van der Meulen - de Jong, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P367: The availability of infliximab trough levels in IBD patients on maintenance therapy deeply impacts therapeutic decision-making
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lobaton T.*1, Cañete F.1, Teniente A.2, Cabre E.1,3, Mañosa M.1, Martínez E.2, Domènech E.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P367: Vedolizumab and early postoperative complications in non-intestinal surgery: A case-matched analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

P.G. Kotze1*, N. Mckenna2, C. Ma1, A. Almutairdi1, L. Raffals3, E.V. Loftus Jr.3, R. Panaccione1, A. Lightner2

Created: Thursday, 21 February 2019, 9:14 AM
P367: Weight patterns in biologicals treated Inflammatory bowel disease cohort
Year: 2021
Source: ECCO'21 Virtual
Authors: Kaazan, P.(1,2);Tan , Z.(3);Maiyani, P.(1);Mickenbecker, M.(1);Edwards, S.(2);McIvor, C.(1);Andrews , J.M.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P368 Tofacitinib induction efficiency and intracellular cytokine dynamics in ulcerative colitis: Results from clinical practice
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Kolar1, M. Lukas1, K. Malickova1,2, L. Prochazkova1, M. Bortlik1,3,4, D. Duricova1, V. Hruba1, N. Machkova1, K. Mitrova1, M. Vasatko1, M. Lukas1,2

Created: Thursday, 30 January 2020, 10:12 AM
P368: Persistence of biologic therapy and mapping of sequential biologic use: Results of a single centre cohort with 841 patients treated over 18 years
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Jenkinson*, N. Plevris, C.S. Chuah, M. Lyons, G. Jones, R. Hall, I. Arnott, C. Lees

Created: Thursday, 21 February 2019, 9:14 AM
P368: Proactive Therapeutic Drug Monitoring is more effective than Conventional Management in Inducing Fecal Calprotectin remission in Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Pedro, J.(1);Rodrigues, I.(1);Fernandes, S.(1);Gonçalves, A.R.(1);Bernardo, S.(1);Baldaia, C.(1);Valente, A.(1);Moura Santos, P.(1);Correia, L.(1);Tato Marinho, R.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P368: Risk factors for serious infections in elderly patients receiving infliximab and other Crohn’s disease therapies: TREAT™ registry data
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Lichtenstein1, W. Langholff2, B. Feagan*3, R. Cohen4, B. Salzberg5, J. Popp6, R. Nissinen7, W. J. Sandborn8

Created: Friday, 22 February 2019, 9:49 AM
P368: Safety issues of azathioprine in patients with inflammatory bowel disease: clinical experience from a referral center
Year: 2022
Source: ECCO'22
Authors: Fousekis, F.(1);Kourtis, G.(1);Saridi, M.(1);Albani, E.(1);Katsanos, K.(1);Christodoulou, D.(1);
Created: Friday, 11 February 2022, 3:52 PM
P368: The presence of extra-intestinal manifestations is associated with poor prognosis in acute severe ulcerative colitis: A KASID multicenter study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kim, D.H.(1);Kim, E.S.(2);Kim, H.S.(3)*;Park, S.H.(4);Kim, S.J.(5);Kim, K.O.(6);Lee, Y.J.(7);Song, E.M.(8);Kim, D.S.(9);Lee, J.(5);
Created: Friday, 14 July 2023, 11:05 AM